Salvage treatment of unfavorable non-Hodgkin's lymphoma with cisplatin, amsacrine, and mitoguazone: A Southwest Oncology Group pilot study

B. W. Dana, S. E. Jones, C. Coltman, W. J. Stuckey

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

We tested the combination of cisplatin, amsacrine, and mitoguazone as salvage treatment for patients with advanced unfavorable non-Hodgkin's lymphomas. An objective response rate of 43% was noted in 30 evaluable patients, but all responses were partial and the median duration of response was only 2 months. Toxicity included life-threatening and fatal leukopenia and severe gastrointestinal intolerance. We conclude that this combination chemotherapy regimen is not a valuable salvage treatment for patients with non-Hodgkin's lymphoma.

Original languageEnglish (US)
Pages (from-to)291-292
Number of pages2
JournalCancer Treatment Reports
Volume70
Issue number2
StatePublished - 1986
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Salvage treatment of unfavorable non-Hodgkin's lymphoma with cisplatin, amsacrine, and mitoguazone: A Southwest Oncology Group pilot study'. Together they form a unique fingerprint.

Cite this